Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raphamin in ARVI in Children Aged 12-18 Years
NCT04918771Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of raphamin in acute respiratory viral infection (ARVI), sponsored by Materia Medica Holding. Primary endpoint: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)) at 14 days. Started Apr 2021; status: completed.
02
Drugs
raphamin
03
Conditions
acute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT04918771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918771.